Validation of the Hartford nomogram in trauma surgery patients

被引:21
作者
Finnell, DL
Davis, GA
Cropp, CD
Ensom, MHH
机构
[1] Univ Kentucky, Med Ctr, Lexington, KY 40506 USA
[2] Univ Kentucky, Coll Pharm, Div Pharm Practice & Sci, Lexington, KY 40506 USA
[3] Shenandoah Univ, Sch Pharm, Winchester, VA USA
[4] Univ British Columbia, Fac Pharmaceut Sci, Div Clin Pharm, Vancouver, BC, Canada
关键词
aminoglycosides; trauma; Hartford nomogram;
D O I
10.1345/aph.17243
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: TO validate the Hartford nomogram for once-daily aminoglycoside dosing in trauma surgery patients. METHODS: A chart review was performed in trauma surgery patients who were started on once-daily aminoglycoside therapy. A peak aminoglycoside concentration was drawn 30 minutes after the end of the first or second infusion, and a random concentration was drawn approximately 10 hours after the dose. The 10-hour random concentration was used to validate the Hartford nomogram by predicting the actual dosing interval (determined by extrapolating the peak and random concentrations to achieve a trough concentration <1 mg/L). The percentage of intervals accurately predicted by the nomogram was determined. RESULTS: Forty-nine patients (34 men and 15 women), age 43.0 +/- 15.9 y, total body weight 81.3 +/- 24.5 kg, ideal body weight 68.1 +/- 10.7 kg, dosing body weight (DBW) 72.0 +/- 14.4 kg, and estimated creatinine clearance (Cl-er) 89.5 +/- 20.6 mL/min/1.73 m(2) were evaluated Patients received 505 +/- 105 mg (7.0 +/- 0.4 mg/kg) of either gentamicin or tobramycin per dose. The concentration 30 minutes after the infusion was 22.4 +/- 5.9 mg/L, the concentration at the end of the dosing interval was 0.20 +/- 0.46 mg/L, the 10-hour random concentration was 2.6 +/- 1.8 mg/L, the elimination rate constant was 0.26 +/- 0.08 h(-1), the elimination half-life was 3.0 +/- 1.2 hours, and the volume of distribution was 19.9 +/- 7.9 L (0.28 +/- 0.09 L/kg of DBW). Ninety-eight percent (48/49) of the intervals were accurately predicted by the nomogram. CONCLUSION'S: In trauma surgery patients with Cl-er of more than 60 ml/min/1.73 m(2), the Hartford nomogram using a single random aminoglycoside concentration accurately predicted the same once-daily aminoglycoside intervals as determined by two concentrations. Less aggressive therapeutic drug monitoring in this patient subpopulation can lead to significant cost savings.
引用
收藏
页码:417 / 421
页数:5
相关论文
共 21 条
[1]   A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides [J].
Ali, MZ ;
Goetz, MB .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (05) :796-809
[2]   A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides [J].
Bailey, TC ;
Little, JR ;
Littenberg, B ;
Reichley, RM ;
Dunagan, WC .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (05) :786-795
[3]   EXPERIENCE OF ONCE-DAILY AMINOGLYCOSIDE DOSING USING A TARGET AREA UNDER THE CONCENTRATION-TIME CURVE [J].
BARCLAY, ML ;
DUFFULL, SB ;
BEGG, EJ ;
BUTTIMORE, RC .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1995, 25 (03) :230-235
[4]   ONCE-DAILY ADMINISTRATION OF AMINOGLYCOSIDES [J].
BATES, RD ;
NAHATA, MC .
ANNALS OF PHARMACOTHERAPY, 1994, 28 (06) :757-766
[5]   AMIKACIN PHARMACOKINETICS IN MORBIDLY OBESE PATIENTS [J].
BAUER, LA ;
BLOUIN, RA ;
GRIFFEN, WO ;
RECORD, KE ;
BELL, RM .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1980, 37 (04) :519-522
[6]   A SUGGESTED APPROACH TO ONCE-DAILY AMINOGLYCOSIDE DOSING [J].
BEGG, EJ ;
BARCLAY, ML ;
DUFFULL, SB .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 39 (06) :605-609
[7]  
CHANDLER MHH, 1996, CLIN PHARMACOKINETIC
[8]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[9]   VARIABILITY IN AMINOGLYCOSIDE PHARMACOKINETICS IN CRITICALLY ILL SURGICAL PATIENTS [J].
DASTA, JF ;
ARMSTRONG, DK .
CRITICAL CARE MEDICINE, 1988, 16 (04) :327-330
[10]   Comparison of creatinine clearance estimation methods in patients with trauma [J].
Davis, GA ;
Chandler, MHH .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1996, 53 (09) :1028-1032